SOUTH SAN FRANCISCO, Calif., April 23 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that Frank Karbe, senior vice president and chief financial officer of Exelixis will present at the 7th Annual Fortis Biotech Conference in London at 3:30 p.m. (GMT) / 7:30 a.m. (PDT) on Wednesday, April 25, 2007.
The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at www.exelixis.com.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in Phase II and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Sankyo. For more information, please visit the company’s web site at www.exelixis.com.
Exelixis, Inc.
CONTACT: investors, Charles Butler, Director, Investor Relations, +1-650-837-7277, or cbutler@exelixis.com, or media, Soleil Maxwell Harrison,Senior Manager, Corporate Communications, +1-650-837-7012, orsharrison@exelixis.com, both of Exelixis, Inc.
Web site: http://www.exelixis.com//
